# Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

> **NCT04248829** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Yuhan Corporation** · enrollment: 393 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib 240 mg/160 mg
- **DRUG:** Gefitinib 250 mg
- **DRUG:** Lazertinib-matching placebo 240 mg/160 mg
- **DRUG:** Gefitinib-matching placebo 250 mg

## Key facts

- **NCT ID:** NCT04248829
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-13
- **Primary completion:** 2022-07-29
- **Final completion:** 2026-06
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248829, "Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04248829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*